Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Pharm-Drugs (Exam 2)
| Question | Answer |
|---|---|
| Chlorpheniramine | H1 Histamine Receptor Antagonist (1st generation) -mild sedative effects -in OTC "cold" drugs -rapidly absorbed orally -ineffective in bronchial ashthma TX: seasonal allergic rhinitis/urticaria |
| Diphenhydramine | H1 Histamine Receptor Antagonist (1st generation) -strong sedative -widely used for oral and paraenteral administration SEs: ototoxicity-not in newborns or w/ antibiotics TX: motion sickness, Parkinsonism, sedation, allergies |
| Promethazine | H1 Histamine Receptor Antagonist (1st generation) SEs: ototoxicity-not in newborns or w/ antibiotics TX: motion sickness, vestibular disturbances, allergies |
| Terfenadine | H1 Histamine Receptor Antagonist (1st generation) -cardiac toxicity when taking in combo with antimicrobial drugs -metabolized to fexofenadine, if CYP3A4 is inhibited -> terfenadine accumulates TX: allergies |
| Desloratadine | H1 Histamine Receptor Antagonist (2nd generation) |
| Fexofenadine | H1 Histamine Receptor Antagonist (2nd generation) -active metabolite of terfenadine (not cardiotoxic) -no sedative effects -lower risk of arrythmia/cardiac effects TX: allergies |
| Loratadine | H1 Histamine Receptor Antagonist (2nd generation) -no sedative effects -longer action -no significant SEs TX: allergies |
| Cetirizine | H1 Histamine Receptor Antagonist (2nd generation) |
| Cromolyn sodium | -inhibit immunologically triggered degranulation of mast cells -used in prophylaxis of bronchial asthma |
| Nedocromil | -inhibit immunologically triggered degranulation of mast cells -used in prophylaxis of bronchial asthma |
| PGF2α | -dec. intraocular pressure; vasoconstriction/bronchoconstriction (inc. Ca2+ or IP3/DAG); inc. contractions (inc. oxytocin) DRUGS: latanoprost |
| PGI | -dec. intraocular pressure; dec. plt aggreg; vasodilation/bronchodilation (inc. cAMP); GI: dec. acid, inc. mucus, inc. blood flow; reprod: dec. tone; kidney: incr. blood flow, inc. diuresis, dec. ADH; inc. temp, dec. NE DRUGS: misoprostil, alprostadil |
| Dinoprostone | synthetic PGE2 administered vaginally for oxytotic effects, collagenase activity -approved for 2nd trimester use as abortifacient -produces uterine contractions (used to induce labor) |
| Latanoprost | stable, long acting PGF2α derivative-treat open angle glaucoma -dec. intraocular pressure -stimulate eyelash growth |
| Misoprostol | PGE1 analog -can be used in combination with meifeprestone (RU486) or methotrexate -> inc. contractions -> abortifacient -provide protection for NSAID induced ulcers (cytoprotective at low dose and inhibits gastric acid secretion at higher doses) |
| Alprostadil | PGE1 analog -administered as a urethral suppository or intracavernous injection to aid in producing erections -maintainence of patent ductus arteriosus -> until surgical correction |
| Treprostinil | PGI2 analog -treatment of pulmonary arterial hypertension -administered using continuous sub-Q delivery |
| Montelukast | leukotriene receptor antagonist -treating asthma by preventing bronchoconstriction and inhibiting bronchial mucal secretions |
| Acetaminophen | not an NSAID because not anti-inflammatory or anti-coagulant -antipyretic and analgesic -inhibits COX-1 and COX-2 -less gastric irritation/bleeding like other NSAIDs -substitute where aspirin is contraindicated -liver toxicity TX: RA, chronic infla |
| Aspirin (acetylsalicylic acid) | NSAID -irreversible inhibitor of COX-1 and 2 -potent anti-coagulant -substantial GI irritation SEs: aspirin-induced asthma (hypersensitivity), Reyes syndrome, salicylism TX: RA, chronic inflamm. -prevent transient ischemic attacks |
| Ibuprofen | non-salicylic NSAID -COX-1 and 2 inhibitor -anti-inflammatory like ASA but less GI irritation -short half-life (2h) and liver metabolized -low dose: analgesic -high dose: analgesic/anti-inflamm SEs: GI, rash, hepatitis... TX: RA, chronic inflam |
| Indomethacin | non-salicylic NSAID -COX-1 and 2 inhibitor -very potent -30% patients have rxns TX: RA, chronic inflamm |
| Naproxen | non-salicylic NSAID -COX-1 and 2 inhibitor -long half life (12h) -free fraction higher in females than males TX: RA, chronic inflamm |
| Non-acetylated salicylates | -no irreversible acetylation of COX enzymes -> less effective than ASA -major advantages: lack of renal toxicity and don't produce NSAID asthma TX: RA, chronic inflamm |
| Celecoxib | Cox-2 selective inhibitor -least potent of these agents, less cardiovascular risks -fewer GI effects, does not effect platelet aggregation -SE: interfere with anti-hypertensive med -> edema, do not give to patients with GI ulcer TX: RA, chronic infla |
| N-Acetylcysteine | for acetaminophen overdose -maintain liver glutathione stores by binding to reactive metabolite as it is produced -can be given 36h after OD, most effective if administered within 8-10h if possible |
| Cyclosporin A | immunosuppressent (T cell inhib.) -inhib. calcineurin phosphatase -> dec. cytokines and impairs response of T cells to antigens TX: GVH, aplastic anemia, organ transplants; autoimmune diseases TOX: rev. nephrotoxicity, neurotoxicity, vasoconstx -> HTN |
| Tacrolimus (FK506) | immunosuppressant (cytotoxic), 100 times more potent than cyclosporin A (similar MOA, USES, TOXICITY, and DRUG INTERACTIONS as cyclosporin A) |
| Azathioprine | immunosuppressant (cytotoxic) -purine antimetabolite (S phase inhibitor), inhibits T and B cell cell cycle/proliferation SEs: myelosupp., coadm. with allopurinal is TOXIC TX: transplant rejection, RA |
| Mycophenolate mofetil (MOA, USES) | immunosuppressant (cytotoxic) -inhibits inosine monophosphate dehydrogenase -> inhibit proliferation of T and B lymphocytes -coadm. cyclosporine or CSs -no coadm. antacids USE: trasplantation rejection (renal) |
| Prednisone (corticosteroid) (MOA and USES) | immunosuppress. and anti-inflamm MOA: regulates of genes with glucocorticoid response elements USE: combo with immunosuppresents for treatment of allograft rejection, autoimmmune disorders, hypersensitivity rxns that produce hives |
| Inteferons | USES: hairy cell leukemia, kaposi's sarcoma, malignant melanomas; IFN-beta used to treat MS TOXICITY: fever, chills, myelosuppression, neurotoxicity |
| Filgastrim (Granulocyte-macrophage colony stimulating factor, GM-CSF) | MOA: cytokine that stimulates clonal expansion and differentiation of hematopoietic cells USES: accelerate recovery of WBC in patients with depressed hematopoiesis (cancer, congential) TOXICITY: hypersensitivity rxns |
| Epoetin alfa | recombinant human erythropoetin MOA: given IV USES: treat anemia resulting from AIDS, renal failure, cancer chemo, prematurity, chronic inflammation TOXICITY: patients may need anticoagulants (hemodialysis), hypertensive patients need readjustment of d |
| Sirolimus (MOA and USES) | -inhibit T cell activation/proliferation USE: transplant rejection (when used in combo with calcineurin inhibitor and GCs), GVHD, autoimmune disease -may produce tolerance |
| FTY720 (MOA) | sphingosine 1-phosphate receptor agonist MOA: reversibly sequesters lymphocytes in lymph nodes and peyer's patches and keeps them out of circulation so that graft is protected form T cell-mediated attack |
| Infliximab/Etanercept (ENEBREL) | Ig against TNF-alpha MOA: prevent cytokine from binding to its receptor USES: combo with methotrexate for RA who do no respond to methotrexate alone, crohn's disease (Infliximab) TOXICITY: serious infections |
| Muromonab-CD3 | Ig against CD3 (mouse monoclonal antibody) -binds to CD3 on T cell and alters CMI -> blocks antigen binding site -> no transplant rejection TOXICITY: cytokine release syndrome-fever, chills, vomiting, headache, weakness |
| Daclizumab | Ig against IL-2 receptor (mouse/human monoclonal antibody) MOA: blocks IL-2 receptor on T cells USE: prevents acute renal transplant rejection, coadmin. with cyclosporine and CSs TOXICITY: well tolerated |
| Rho (d) immune globulin | Ig against anti-D antibodies MOA: block response of an Rh-neg mother to a RH-positive baby USE: prevent hemolytic disease of newborn |
| Bacillus Calmette-Guerin | strain of byobacterium bovis MOA: stimulates T cells and NK cells USES: used for bladder cancer patients TOXICITY: severe hypersensitivity and shock |
| Interleukin-2 (Aldeslleukin) | -promotes T and B cell proliferation, differentiation, recruitment of NK cells, thymocytes USES: AIDS and cancer patients TOXICITY: fever, nausea, vomiting, malaise |
| Cyclosporin A (DRUG INTERACTIONS) | DRUG INTERACT.: erythomycin, ketoconazole, amphotericin B inhibit metabolism in liver -> increase in drug's toxicity; drugs that accelerate clearance -> transplant rejection -do not give cyclosporine and sirolimus at same time (increase other drug's S |
| Mycophenolate mofetil (TOXICITY, DRUG INTERACTIONS) | TOXICITY: diarrhea, leukopenia, CMV infection, GI hemmorage DI: coadm. w/ antacids containing magnesium and aluminum hydroxides decreases absorption |
| Prednisone (corticosteroid) (TOXICITY) | TOXICITY: chronic use (beyond 2 weeks) associated with increased infections, formation of ulcers, induction of hyperglycemia and osteroperosis |
| Sirolimus (TOXICITY and DRUG INTERACTIONS) | TOXICITY: dose-dependent thrombocytopenia, leukopenia, hyperlipidemia DI: substrate for CYP3A4 -> affected by any drug that inhibit/induces this enzyme -should not be given with cyclosporine or ketoconazole |
| FTY720 (USES and TOXICITY) | USES: used with cyclosporine and prednisone for prevention of acute organ rejection in transplant patients TOXICITY: reversible lymphopenia and increased heart rate |
| Indomethacin | NSAID -immediate relief of pain and inflammation -not mandatory in tx of RA, adjuvant |
| Naproxen | NSAID -immediate relief of pain and inflammation -not mandatory in tx of RA, adjuvant |
| Celecoxib | NSAID -immediate relief of pain and inflammation -not mandatory in tx of RA, adjuvant |
| Prednisone | glucocorticoid, corticosteroid -fast action for severe inflammation when NSAIDs are contraindicated, serious systemic manifestations (vasculitis, pericarditis), bridge therapy, when all other medical means are exhausted |
| Azathioprine | traditional DMARD -for refractory RA or systemic involvement |
| Cyclosporine | traditional DMARD -limited use |
| Methotrexate | traditional DMARD MOA: inhibits dihydrofolate reductase -standard of care for early therapy of RA -> response in 4-6 weeks -low doses decrease symptoms, preserve joints, improve outcome |
| Sulfasalazine | traditional DMARD -antimalarial: anti-inflammatory, immunomodulator -moderately effective for mild RA -used in combo with methotrexate -may require 2-3 months for response -more toxic than hydroxychloriquine -use during pregnancy is safe |
| Etarnercept | biological DMARD (TNF-alpha inhibitor) -fusion protein-contains ligand-binding sequence of human TNF-alpha receptor fused to human IgG1 -binds TNF-alpha, prevents it from activating its receptors -monotherapy or combo with methotrexate -numerous SEs |
| Adalimunab | biological DMARD (TNF-alpha inhibitor) -humanized anti-TNF-alpha monoclonal antibody -does not contain non-humna or artificial sequences -monotherapy or combo with methotrexate -numerous SEs |
| Infliximab | biological DMARD (TNF-alpha inhibitor) -chimeric anti-TNF-alpha monoclonal antibody -combo with mexotrexate for patients that do no respond to methotrexate alone -numerous SEs |
| Anakinra | biologic DMARD (IL-1 inhibitor) -competitively inhibits pro-inflammatory effects of IL-1 -monotherapy or combo with methotrexate -not given with TNF inhibitor -modest improvements in signs/symptoms -considered least effective DMARD -infrequently use |
| Abatacept | biological DMARD (selective costimulation) -fusion protein-homologue of CD28 (T cell receptor for B7) -> binds B7 with higher affinity than CD28 -> interferes with T-cell activation -> inhibits production of TNF-alpha, IFN-gamma, IL-2 |
| Rituximab | biological DMARD (CD20 antibody) -chimeric monoclonal antibody against CD20 on surface of B cells -combination with methotrexate -no combo with other biologic DMARD -fatal infusion rxns -increased risk of infection, reactivation of Hep B infection |
| Prednisone (TOXICITY) | high doses: mineralcorticoid effects -increased susceptibility to infection, inhibits growth, induces myopathy, osteroporosis, acute adrenal insufficiency |
| Methotrexate (TOXICITY) | adverse SEs even at low doses -bone marrow suppression: leukopenia, thrombocytopenia, anemia -hypersensitivity pnemonia -teratogenic -avoid alcohol -> hepatic toxicity |
| Abatacept (TOXICITY) | -not given with another biologic DMARD -infusion rxs: hypertension, headache, anaphylaxis (rare) -increased risk of serious infections |
| Cancer Regimens (MOPP) | mechloretamine, oncovin, prednisone, procarbazine TX: hodgkin's disease (lymphoma) |
| Cancer Regimens (CVPP) | cyclophosphamide, vincristine, prednisone, procarbazine TX: hodgkin's disease, non hodgkin's disease |
| Cancer Regimens (CMF) | cyclophosphamide, methotrexate, 5-fluorouracil TX: breast cancer (in post-menopausal women with no estrogen receptors) |
| Cancer Regimens (ABVD) | adriamycin, bleomycin, vinblastine, dacarbazine TX: lymphomas, sarcomas |
| Cancer Regimens (FAM) | 5-fluorouracil, adriamycin, mitomysin TX: colon cancer |
| Cancer Regimens (CMV) | cisplatin, methotrexate, vinblastine |
| Cancer Regimens (FAC) | 5-fluorouracil, adriamycin, cyclophosphamide |
| mechlorethamine (nitrogen mustards) | phase non-specific -affects DNA synthesis and cell cycle -bifunctional agents produce cross-linking b/w DNA strands or b/w DNA and protein resulting in cytotoxicity TX: MOPP -> hodgkin's disease TOXICITIY: bone marrow and GI |
| cyclophosphamide, ifosfamide (nitrogen mustards) | phase non-specific -crosslinks DNA/RNA strands TX: non-hodgkin's lymphona, breast/ovarian cancer (CMF, CVPP), RA TOXICITY: tall lean cyclist has bladder problems and goes to the men's (MENSA) room (acrolein->hemmorhagic cystitis), immunosupp and alope |
| melphalan (nitrogen mustards) | phase non-specific TX: multiple myeloma and ovarian cancer TOXICITY: nausea and bone marrrow suppression |
| carmustine, loumustine (nitrosoureas) | phase non-specific -alkylate DNA, produce strand breaks and inhibit protein syn. TX: brain tumors (highly lipophilic) TOXICITY: severe myelosuppression, long-term use -> renal failure |
| busulfan | phase non-specific -crosslinks strands of DNA TX: CML TOXICITY: high doses -> pulmonary fibrosis |
| procarbazine | phase non-specific -inhibits DNA/RNA/protein synthesis TX: hodgkin's (MOPP, CVPP), non-hodgkin's, small cell lung cancer, malignant melanoma, brain tumors TOX: bone marrow depress, acetaldehyde accum, inhib. MO and cytochrome P450 (no drugs or drinkin |
| dacarbazine (triazenes) | phase non-specific -methylate DNA TX: hodgkin's |
| cisplatin, carboplatin (platinum complexes) | phase non-specific -form intra/interstrand DNA crosslinks -> dec DNA/RNA synth, produce DNA breaks TX: testicular tumors (coadm. vinblastine and bleomycin), ovarian CA (coadm. cyclophosphamide), SCLC, bladder CA TOX: ototoxic, nephrotox, electrolyte di |
| methotrexate (folic acid analogs)-antimetabolite | -inhib DHFR (S phase specific) TX: cures osteosarcoma, choriocarcinoma; tx ALL, burkitts, non-hodgkin's, bladder CA, breast CA (CMF); low dose-RA and psoriasis TOX: myelosupp, nausea/diarr/fatigue, neurotoxic, chronic adm.-> hepatic fib -leucovorin res |
| leucovorin (folate antagonist rescue agent)-antimetabolite | used to reverse effects of methotrexate by bypassing the blocked DHFR |
| 6-mercaptopurine (6-MP) (purine analogs) | S phase specific -decrease purine synthesis TX: ALL TOX: bone marrow depression, gout (treat with allopurinol) |
| 6-thioguanine (6-TG) (purine analogs) | S phase specific -inhibit purine synthesis TX: coadmin. cytarabine and daunorubicin for acute ganulocytic leukemia TOX: bone marrow immunosuppression |
| 5-fluorouracil, capecitabine (5-FU) (pyrimadine analogs) | S phase specific -inhibit thymidylate synthase -> dec DNA synthesis and cell death TX: breast CA (CMF), colon or rectum CA (FAM), colon CA pts on cimetidine (hrtburn)have inc rate of survival TOX: myelosuppress, GI tract toxicity |
| cytarabine (AraC) (pyrimadine analogs) | S phase specific -incorporate into DNA and terminates chain elongation TX: acute leukemia (coadm. 6-TG) TOX: severe myelosuppression |
| gemcitabine (pyramidine analogs) | NOT S phase specific -inhibits DNA polymerase and ribonucleotide reductase (terminates elongation) TX: metastatic pancreatic CA (1st line) and non-small cell lung CA TOX: myelosupp, flu-like syndrome, mild elevation in liver transaminases |
| vincristine (vinca alkaloids) | M phase-specific -reversibly bind tubulin and blocks polymerization into MT TX: childhood ALL (1st line), hodgkin's (MOPP), acute myelogenous leuk, hodgkin's, pediatric solid tumors, some adult solid tumors TOX: peripheral neuropathy |
| vinblastine (vinca alkaloids) | M phase-specific -reversibly bind tubulin and blocks polymerization into MT TX: cures testicular tumors (coadm. bleomycin, cisplatin); hodgkin's, non-hodgkin's, choriocarcinoma TOX: bone marrow suppression |
| paclitaxel, docetaxel (taxanes) | M phase-specific -promotes MT formation and stabilization TX: ovarian and breast CA TOX: neutropenia (give G-CSF), hypersensitivity (give dexamethasone/diphenhydramine/H2 blocker) |
| etoposide (podophyllotoxins) | S/G2 phase-specific -inihibits topoisomerase II -> block DNA replication TX: testicular tumors (coadm. bleomycin and cisplatin), SCLC (coadm. cisplatin and ifosfamide) TOX: dose-limiting myelosuppression |
| topotecan, irinotecan (camptothecins) | -inihibit topoisomerase I -> block DNA replication TX: colorectal CA (after 5-FU treatment), ovarian and advanced SCLC TOX: myelosupp, alopecia, nausea, vomiting, cholinergic sym, mucositis, bronzing of skin |
| bleomycin | G2 phase-specific -binds DNA, generates free rad and produces strand breaks, inhib ATP-dependent DNA ligase -> prevent DNA repair, cells accumulate in G2 TX: cures testicular CA (coadm. cisplatin and vinblastine); squamous carcinomas and lymphomas |
| bleomycin (TOXICITY) | TOX: pneumonitis and pulmonary fibrosis (may be fatal); hyperpigmentation, stomatitis, alopecia, LEAST MYELOSUPP ACTIVITY |
| Actinomycin D (Dactinomycin) (DNA-binding antibiotics) | inhibits DNA/RNA synthesis TX: cures Wilm's tumor and rhabdomyosarcoma (coadm. vincristine and cyclophosphamide after surgery/radiotherapy); methotrextae-resistant choriocarcinoma TOX: myelosupp |
| Adriamycin (Doxorubicin) (anthracyclines) | -intercalate with DNA and blocks DNA/RNA synthesis TX: myelomas, sarcomas, lymphomas (ABVD, FAM) TOX: cardiotoxicity, myelosupp, severe alopecia |
| Daunorubicin (anthracyclines) | -intercalate with DNA and blocks DNA/RNA synthesis TX: acute leukemias TOX: cardiotoxicity, myelosupp, severe alopecia |
| Hydroxyurea (miscellaneous antineoplastic agents) | ? |
| L-asparaginase (miscellaneous antineoplastic agents) | -metabolizes L-asparagine required by tumor cells and dec levels of asparagine synthetase TX: ALL (coadm. vincristine and prednisone) TOX: hypersensitivity resulting from its antigenicity |
| Thalidomide (miscellaneous antineoplastic agents) | ? |
| Vorinostat (miscellaneous antineoplastic agents) | ? |
| Bortezomib (proteasome inhibitors) | -reversible inhibitor of 26 S proteosome and prevents activation of NF-kB TX: multiple myeloma TOX: nausea, diarrhea, muscle weakening, myelosupp, peripheral neuropathy, fever, anorexia, anemia, constipation |
| Imatinib mesylate (GLEEVEC) (protein tyrosine kinase inhibitors) | blocks Bcr-Abl kinase -phosphorylates proteins that cause cell proliferation (blocks this) TX: CML; GI stromal sarcoma TOX: nausea, edema, muscle cramps, rash, diarrhea, myelosupp DI: inc warfarin, itraconz and erythro -> inc IM, phenytoin -> dec I |
| Gefitinib (protein tyrosine kinase inhibitors) | blocks EGFR kinase TX: non small cell lung CA TOX: well tolerated, diarrhea, acne-like rash -works best in asian nonsmokers DI: inducers of P450 decrease serum conc of drug |
| Erlotinib (protein tyrosine kinase inhibitors) | ? |
| Sunitinib (protein tyrosine kinase inhibitors) | blocks VEGFR and PDGFR kinase TX: RCC, GI stromal tumors TOX: fatigue, anorexia, nausea, diarrhea, mucositis, stromatitis DI: ketoconz -> inc drug, rifampin -> dec drug |
| Sorafenib (protein tyrosine kinase inhibitors) | blocks cell surface and intracellular kinases TX: RCC TOX: fatigue, diarrhea, dermatologic hypertension, neutropenia, bleeding |
| Lapatinib (protein tyrosine kinase inhibitors) | ? |
| Trastuzumab (monoclonal antibodies) | blocks HER2/neu receptor TX: breast CA TOX: very few-fever and chills, cardiotoxicity when coadm. adriamycin |
| Rituximab (monoclonal antibodies) | blocks CD20 receptor TX: low grade non-hodgkin's B cell lymphoma TOX: fever, chills, nausea on first infusion |
| Cetuximab (monoclonal antibodies) | blocks EGFR receptor (EGFR overexpressed in colorectal CA) TX: colorectal CA TOX: acne-like skin rash |
| IFN-alpha (bilogical response modifiers) | TX: hairy cell leukemia, kaposi's sarcoma, melanoma (malignant) TOX: fever and chills, myelosupp, neurotoxicity |
| IL-2 (biological response modifiers) | -induces a T cell response cytolytic for tumor cell TX: melanoma (malignant), renal cell CA TOX: hypotension, arrythmias, peripheral edema, elevated liver function, anemia, thrombocytopenia, nausea, diarrhea, fever |
| G-CSF (biological response modifiers) | -expands pop of neutrophil granulocyte precursors and augments granulocyte function TX: prophylaxis of chemotherapy-induced neutropenia TOX: bone pain in lower back, sternum, pelvis |
| Tamoxifen (selective estrogen receptor modulators) | estrogen antagonist -inhibits expression of TGF and IGF-1 and inhibits breast CA growth TX: breast CA (post-men, in ER+ tumors) TOX: nausea, hot flashes, vaginal bleeding, skin rases, hypercalcemia, incresed risk of endometrial CA |
| aminoglutethimide (aromatase inhibitors) | inhibits desmoloase and aromatase -> dec estradiol TX: breast cancer (post-men, in ER+ tumors) TOX: CNS depression (drowsiness, visual blurring, ataxia) |
| anastrozole (aromatase inhibitors) | TX: breast CA (post-men, in ER+ tumors) TOX: GI disturbanes, lack of bodily strength, headaches, bone and back pain -reduced incidence of developing blood clotting and vaginal bleeding compared to Tamoxifen |
| prednisone (GCs) | -converted to prednisolone, binds receptor TX: pt of MOPP and CVPP regimens for hodgkins/non-hodgkin's lymphomas TOX: cushing's syndrome; immunosupp |
| Leuprolide, Goserelin (long-acting gonadotropin releasing hormone analogs) | cause testosterone and estrogen production to drop TX: prostate cancer TOX: not very toxic, sexual dysfunction, transient flare of disease after initial dose prevented by coadm. flutamide, |
| Flutamide (antiandrogens) | blocks DHT binding to receptors TX: prostate CA TOX: GI distress |
| Tamoxifen (benefits) | dec osteoporosis, decreased serum and LDL cholestrol, increased apolipoprotein A1 (prevent heart disease) |
Created by:
8403333
Popular Pharmacology sets